{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001872","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.680760+00:00","generated_at":"2026-06-20T18:39:58.163619+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagonist Therapeutics Chief R&D Strategy Officer David Liu transitions to part-time advisor due to health reasons","bullets":["David Liu stepped down as Chief R&D Strategy Officer effective Jan 1, 2023, due to health reasons.","He will continue as a part-time R&D Strategy Advisor, no longer an executive officer.","No replacement named for the role of Chief R&D Strategy Officer.","Liu is no longer a Section 16 officer, reducing executive team."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001872","json":"https://secwatch.observer/filing/0001104659-23-001872.json","markdown":"https://secwatch.observer/filing/0001104659-23-001872.md","text":"https://secwatch.observer/filing/0001104659-23-001872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/0001104659-23-001872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/tm232306d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:39:58.163619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9276edc24","claim":"David Liu changed role as Chief R&D Strategy Officer at Protagonist Therapeutics, Inc.","evidence_excerpt":"Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.’s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923001872/0001104659-23-001872-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to a part-time R&D Strategy Advisor"},{"label":"Role","value":"Chief R&D Strategy Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}